Lewy body disease
Drug research and approvals for lewy body disease: what is recruiting, what Health Canada authorized, FDA orphan designations and EU medicines. See every condition.
As of Nov 22, 2026, 97 studies of lewy body disease are recruiting on ClinicalTrials.gov, and Health Canada has authorized 0 drug trials for it since 2013.
- Recruiting worldwide: 97
- Trials authorized in Canada: 0
- FDA orphan approvals: 0
- EU medicines: 0
- Correlation Between Visual Reading and DOlab Software Quantitative Analysis of DaT-SPECT ImagesNCT07943702 · Not reported · Dorian Technologies S.r.l. · starts Oct 13, 2026
- Automated Language Analysis in Neurodegenerative Diseases: Application of Artificial Intelligence ModelsNCT07906769 · Not applicable · Istituti Clinici Scientifici Maugeri SpA · starts Oct 20, 2025
- MK-0947 PN-002: An Open-label Study to Evaluate Brain α-synuclein Deposition Using Positron Emission Tomography (PET)…NCT07880379 · Phase 1 · XingImaging, LLC · starts Aug 25, 2026
- Visual Hallucinations in Lewy Body DiseasesNCT07849413 · Not reported · NYU Langone Health · starts Sep 15, 2026
- Multi-Center Study of Natural History in Atypical Parkinsonian Syndromes (MAPS-NH)NCT07805967 · Not reported · Second Affiliated Hospital of Soochow University · starts Nov 12, 2025
- Biofluid Research on Age-Related or Inherited NeurodegenerationNCT07798700 · Not reported · University of Pennsylvania · starts Dec 12, 2025
- A Comprehensive, Multimodal Characterization of Prodromal PD in Subjects With RBDNCT07790744 · Not reported · Danish Research Centre for Magnetic Resonance · starts Feb 1, 2026
- Futibatinib (TAS-120) in Patients With Advanced Biliary Tract CancerNCT07710885 · Phase 3 · Taiho Pharmaceutical Co., Ltd. · starts Jun 24, 2026
- Prospective Multicenter Registry Study of Multiple System Atrophy in ChinaNCT07644013 · Not reported · Peking University First Hospital · starts Jun 1, 2025
Approved 1
- IoflupaneDiagnostic agent
Phase 3 1
- GalantamineAcetylcholinesterase inhibitor
Phase 2 3
- NeflamapimodMAP kinase p38 alpha inhibitor
- NelotanserinSerotonin 2a (5-HT2a) receptor inverse agonist
- MevidalenDopamine D1 receptor positive allosteric modulator
Phase 1 or earlier 5
- TerazosinAdrenergic receptor alpha-1 antagonist
- Microcrystalline cellulose
- Ambroxol
- IrsenontrinePhosphodiesterase 9A inhibitor
- Fosgonimeton
How its trials ended
196 ClinicalTrials.gov studies of the condition, classified by TrialPanorama, partly automatically, so some labels are wrongOf the 19 whose ending is known, 32% met their primary endpoint, 16% missed it and 53% stopped early.
- Ongoing8845%
- Completed, result not reported7237%
- Status unknown179%
- Met its primary endpoint63%
- Stopped: other or unclear53%
- Missed its primary endpoint32%
- Stopped: lack of efficacy21%
- Stopped: enrollment or feasibility21%
- Stopped: funding11%
Condition names come from Health Canada's trial database. Orphan designations and EU medicines are matched when their indication names the condition as whole words, so a broader or differently worded indication can be missed. Recruiting counts are live from ClinicalTrials.gov's own condition search, refreshed daily. ClinicalTrials.gov, Health Canada Clinical Trials Database, FDA orphan designations, EMA